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Abstract
The present work investigates the effect of malondialdehyde (MDA) binding on the enzymic activity and on some
structural properties of glucose 6-phosphate dehydrogenase (G6PD). We studied whether K-crystallin could protect the
enzyme against MDA damage, and if so, by what mechanism. We also studied whether K-crystallin could renature G6PD
denatured by MDA. K-Crystallin was prepared from bovine lenses by gel chromatography. MDA was freshly prepared and
incubated with G6PD with or without K-crystallin. The results show that MDA reacted with G6PD non-enzymically causing
inactivation at concentrations lower than those used previously on structural proteins. The modified enzyme became
fluorescent. K-Crystallin, acting as a molecular chaperone, specifically protected the enzyme against inactivation by MDA.
The enzyme was not reactivated by K-crystallin, but it was stabilised and protected against further denaturation. Complex
formation between K-crystallin and the modified enzyme was demonstrated by immunoprecipitation. G6PD was very
susceptible to MDA and we have shown for the first time that K-crystallin is able to protect the enzyme against this
damage. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Free radical damage to various tissues has been
implicated in the pathogenesis of several diseases in-
cluding diabetes [1,2], atherosclerosis [3], Alzheimer
disease [4], cataract [5], and retinal degeneration [6].
The toxic e¡ects of the reactive forms of oxygen are
removed by various scavengers, including ascorbic
acid, vitamin E, glutathione, superoxide dismutase
(SOD) and catalase [7].
Glutathione (GSH) is a tripeptide involved in
many cellular functions and protects proteins and
other cellular components against oxidative damage.
Oxidation converts GSH to the disulphide form,
GSSG, which is recycled via the glutathione reduc-
tase reaction. GSH regeneration requires NADPH,
mostly produced in the pentose phosphate pathway
catalysed by glucose 6-phosphate dehydrogenase
(G6PD), and 6-phosphogluconate dehydrogenase
(6PGD). Decreased levels of GSH have been re-
ported in human cataract lenses, and in the blood
of the subjects with diabetes and arthritis [8]. These
decreases could have various causes. The low level of
NADPH, due to a decreased activity of G6PD and
6PGD, could contribute to the failure of GSH regen-
eration. A decreased activity of G6PD has been re-
ported in cataract [9,10] and in the lens with age [11].
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Malondialdehyde (MDA) is one product of lipid
peroxidation and is a by-product of thromboxane
synthesis [12]. It reacts with amino groups of a vari-
ety of proteins causing increased £uorescence, cross-
linking and aggregation [13^16]. Proteins modi¢ed
by MDA have been identi¢ed in diabetes [17], cata-
ract [18] and atherosclerotic plaque [19]. Most of
these proteins are structural proteins, which are not
only abundant, but also long-lived.
The e¡ect of MDA on G6PD has not been previ-
ously studied. Our studies on post-translational mod-
i¢cation of enzymes demonstrated inactivation of a
variety of enzymes by sugars [20^22], cyanate [23]
and steroids [24]. The inhibition of two glycolytic
enzymes by aldehydes has been reported but it is
not clear that this was inactivation by post-transla-
tional modi¢cation [25]. It has been shown that
4-hydroxy-2-nonenal (HNE), another major product
of oxidation of polyunsaturated fatty acids, inacti-
vates G6PD and causes increased £uorescence [26].
The mechanism of G6PD inactivation by HNE, an
K,L-unsaturated aldehyde, a product of lipid per-
oxidation, involves the reaction between the nucleo-
philic residue on the enzyme and the double bond
(C-3) of HNE, rather than the reaction between pro-
tein and the carbonyl group of HNE [26].
Unlike HNE, MDA is a saturated aldehyde, which
in aqueous solutions can exist in various forms, de-
pending on the pH. In neutral and alkaline solutions
the predominant form is enolate anion:
OxCHÿ CH2 ÿ CHxOH
HOÿ CHxCHÿ CHxOH
3Oÿ CHxCHÿ CHxO enolate anion
A similar mechanism could also explain the MDA
binding to proteins.
K-Crystallin is a major structural protein in verte-
brate eye lens, and it is also present in non-lenticular
tissues such as heart, lung, brain, kidney, etc. [27]. It
shares both sequence and secondary structural ho-
mology with small heat-shock proteins (sHSPs) and
has similar activity. K-Crystallin can serve as a mo-
lecular chaperone protecting proteins against heat-
induced aggregation [28]. It can also protect enzyme
activity against attack by sugars and other com-
pounds [20^24]. The quaternary structure of K-crys-
tallin is not known yet, but several models have been
proposed [29]. One of these models is based on its
activity as a molecular chaperone, and is similar to
that of GroEL, the best characterised molecular
chaperone. The model consists of a cylinder formed
of two rings, with about 20 monomers (20 kDa each)
in each ring [30]. The cavity could protect the pro-
teins from unfolding and denaturation.
Very recent data support this mechanism. Cryo-
electron microscopical analysis of the quaternary
structure of human recombinant KB-crystallin
showed a variable monomer packing, revealing the
presence of a large cavity [31]. The crystal structure
of a sHSP from Methanococcus jannaschii, which
shows 21% sequence identity with human KA-crys-
tallin, has been reported [32]. The protein is a hollow
spherical complex composed of 24 subunits. One of
the mechanisms suggested to explain its ability to
protect other proteins from denaturation is that the
proteins under stress may get trapped inside or on
the surface of the globular protein.
In the present work we investigated the e¡ect of
MDA binding on the structural properties and on
the enzymic activity of G6PD. The protective e¡ect
of K-crystallin against the inactivation of the enzyme
by MDA, and the possible renaturation of the
MDA-denatured enzyme, were investigated.
2. Materials and methods
2.1. Chemicals
G6PD (bovine adrenal), glucose 6-phosphate,
1,1P,3,3P-tetraethoxypropane, Freund’s adjuvant,
protein A agarose and all other chemicals were
from Sigma Chemical Co. (Poole, Dorset, UK) un-
less otherwise indicated. TSK-HW55 was from BDH
Chemicals (Poole, Dorset, UK). Filter units of
0.22 Wm were from Millipore.
2.2. Preparation of malondialdehyde
MDA was prepared as described by Riley and
Harding [14] by acid hydrolysis of 1,1P,3,3P-tetra-
ethoxypropane for 24 h at room temperature. The
pH of the solution was adjusted to 7.4 with NaOH
and bu¡ered with 0.1 M sodium phosphate bu¡er,
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pH 7.4. No NaN3 was added. The ¢nal concentra-
tion of MDA was 100 mM. The solution was made
freshly each week to avoid polymerisation.
2.3. Isolation and puri¢cation of K-crystallin
Bovine lenses were gently homogenised in 0.1 M
sodium phosphate bu¡er, pH 7.6 (1/7, w/v) in a
hand-operated homogeniser, and the homogenate
was centrifuged at 20 000Ug for 30 min at 4‡C. K-
Crystallin was separated from supernatant by gel
chromatography on TSK-HW55 as described by Bes-
wick and Harding [33]. Proteins were eluted at a £ow
rate of 20 ml/h; fractions of 3 ml were collected and
absorbance at 280 nm was measured. The fractions
contributing to K-crystallin peak were pooled, exten-
sively dialysed and freeze-dried. The SDS-PAGE
showed a slight contamination of K-crystallin with
L-crystallin. The freeze-dried material was dissolved
in 0.1 M sodium phosphate bu¡er, pH 7.6 and
loaded onto the same TSK-HW55 column. The sep-
aration was performed under the same conditions as
mentioned above. SDS-PAGE showed that pure K-
crystallin had been obtained.
2.4. MDA binding to G6PD
G6PD (200 Wg protein) was incubated in 100 mM
phosphate bu¡er, pH 7.4 with 2.5 mM MDA in ster-
ile vials, in a shaking water bath at 37‡C, for 4 h.
Triplicate aliquots were removed from the incubation
mixture after 30 min, 1, 2, 3 and 4 h and the bound
MDA was determined by the thiobarbituric acid pro-
cedure as previously described [14]. The bound MDA
concentration was estimated by comparing the ab-
sorption at 535 nm against a standard curve analysed
under similar conditions with known concentrations
of MDA.
2.5. Enzyme incubation with or without K-crystallin,
and activity assay
A mixture containing G6PD (0.625 units), 0.55
mM NADP and 100 mM phosphate bu¡er, pH
7.4, in a total volume of 2.5 ml, was ¢ltered through
0.2 Wm pore size Millipore ¢lters into sterilised glass
vials, and incubated at 37‡C in a shaking water bath.
In some cases, the incubation mixture also contained
MDA and/or K-crystallin at the concentrations men-
tioned for each experiment. Bovine serum albumin
(BSA), lysozyme and K-crystallin, respectively, were
present in one experiment at a concentration of 2 Wg/
ml. The enzymic activity was determined by the
method of Langdon [34]. The reaction mixture
(3 ml) consisted of 2 ml incubation mixture made
up to 6.7 mM in MgCl2 and 1 mM glucose 6-phos-
phate was added prior to the assay. The activity was
estimated from the increase in absorption at 340 nm,
resulting from the formation of NADPH, over 2 min,
and expressed as a percentage of the activity at zero
time for each incubation mixture. All assays were
carried out in triplicate.
2.6. G6PD refolding experiments
In order to determine if K-crystallin could refold
G6PD with recovery of the activity lost by MDA
binding, ¢rst the enzyme incubated for 6 h with
1 mM MDA was dialysed to remove the unbound
MDA, and then it was incubated for 18 h with
K-crystallin (50 Wg/ml). A control containing the
dialysed sample without K-crystallin was incubated
in parallel. The experiment was repeated four
times.
2.7. Fluorescence spectrophotometry
G6PD (0.184 mg/ml) was incubated for 6 h at
37‡C in 8.8 mM NADP with 5 mM MDA in
0.1 M phosphate bu¡er, pH 7.4, in the presence or
absence of K-crystallin (50 Wg/ml) in a total volume
of 0.2 ml. After incubation, the samples were exten-
sively dialysed against distilled water, at 4‡C (over-
night, 6 changes). The dialysed samples were diluted
to 0.5 ml with distilled water, and the £uorescence
was analysed using a Perkin Elmer spectro£uorime-
ter with all band widths set at 10 nm.
The amount of MDA bound to G6PD and to
K-crystallin was estimated by incubating G6PD
with 5 mM MDA, K-crystallin with 5 mM MDA,
and G6PD plus K-crystallin with 5m M MDA, under
the same conditions mentioned above. The samples
were dialysed overnight, diluted to 1 ml with 0.1 M
phosphate bu¡er, pH 7.4 and the bound MDA
measured by the thiobarbituric acid (TBA) method
[14].
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2.8. Immunoprecipitation
The speci¢c immune serum, anti-G6PD, was raised
in rabbits by subcutaneous injections of 50 Wg en-
zyme in 0.5 ml 0.14 M NaCl emulsi¢ed with 0.5 ml
Freund’s complete adjuvant, and three booster injec-
tions of enzyme emulsi¢ed in Freund’s incomplete
adjuvant, at 3-week intervals. IgG was puri¢ed
from antisera by caprilic acid precipitation [35], fol-
lowed by ammonium sulphate precipitation.
Samples containing G6PD (190 Wg protein/ml),
10 mM NADP and 100 mM phosphate bu¡er, pH
7.4, in a total volume of 0.2 ml were incubated with-
out or with 2 Wg/ml K-crystallin, with 1 mM MDA
respectively, for 6 h at 37‡C.
The unreacted MDA was removed by dialysis
(10 changes) against distilled water, at 4‡C. After
dialysis, samples were diluted to 0.5 ml with 100
mM phosphate bu¡er, pH 7.4, and incubated with
10 Wl antiserum for 2 h at 4‡C, to allow immune
complexes to form. To precipitate immune com-
plexes, 40 Wl protein A agarose was added to each
sample and incubated for 6 h at 4‡C. The incubation
mixture was centrifuged for 10 min at 11 600Ug, at
4‡C, and immune precipitate was washed by centrif-
ugation and resuspension, twice with each of the
following solutions: PBS, 0.5 M NaCl in PBS and
PBS containing 1% Triton X-100, 0.5% sodium de-
oxycholate and 0.1% SDS [36].
2.9. SDS-PAGE
The pellets obtained from the last centrifugation
were suspended with SDS sample bu¡er at double
the normal concentration, and the SDS-PAGE was
performed in 15% polyacrylamide according to
Laemmli [37] with a Bio-Rad Mini-Protean II appa-
ratus, at 200 V, constant voltage, for 45 min. The
gels were stained with 0.1% Coomassie brilliant blue
R-250 and destained with 40% methanol in 10%
acetic acid.
3. Results and discussion
3.1. Inactivation of G6PD by MDA
MDA, HNE and 4-hydroxyhexenal are formed
during lipid peroxidation [38]. MDA forms Schi¡-
base adducts with lysine residues and crosslinks pro-
teins in vitro [15,16]. The modi¢cation inactivated
ribonuclease, crosslinked it, and gave it a new £uo-
rescence [16]. Recently, some MDA-lysine adducts in
proteins were characterised [39,40]. MDA bound
progressively to G6PD over 4 h of incubation with
2.5 mM MDA at pH 7.4 (Fig. 1). After 4 h of in-
cubation 1.2 mol MDA was bound per mol enzyme
dimer (Fig. 1).
The e¡ect of various concentrations of MDA in-
cubated for 4 h with G6PD on the enzymic activity is
shown in Fig. 2. MDA inactivated the enzyme, and
the amount of inactivation increased with MDA con-
centration. The lowest MDA concentration (1 mM)
induced 50% inactivation, and the activity decreased
further with higher MDA concentrations. The con-
trol with MDA added to the reaction mixture imme-
diately prior to the assay showed no inactivation,
suggesting that MDA was not an inhibitor. The ly-
sine and arginine residues of G6PD are important for
its activity, one of the lysine residues being involved
in substrate binding [41]. Conformational changes
induced by MDA binding to lysine amino groups
could disrupt hydrophobic forces stabilising the in-
teraction between subunits in the active dimer of
Fig. 1. Binding of MDA after incubation of G6PD (200 Wg
protein/ml) in 100 mM sodium phosphate bu¡er, pH 7.4, with
2.5 mM MDA for 0^4 h, at 37‡C.
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G6PD. It seems that aldehydes inactivate the enzyme
either via Schi¡-base formation (MDA) or Michael
addition (HNE); in the case of dialdehydes both re-
actions may occur simultaneously [42].
Our results show that when MDA is formed in
tissues or if it enters tissues, it will not simply modify
structural proteins, it will also inactivate enzymes.
The inactivation was studied here at lower concen-
trations than used previously to study e¡ects on
structural proteins [14], indicating that enzymes like
G6PD may be especially susceptible to this damage.
3.2. The e¡ect of K-crystallin on G6PD inactivation
by MDA
The chaperone activity of K-crystallin was demon-
strated at ¢rst by protecting proteins against heat-
induced aggregation [28]. Recently it was found
that K-crystallin protected enzymes against inactiva-
tion by glycation [20^22] and by carbamylation [23]
or steroid binding [24]. The e¡ect of K-crystallin on
enzyme inactivation by MDA binding has not been
reported so far.
K-Crystallin protected against the MDA-induced
inactivation of G6PD. The enzyme was incubated
for 6 h with 1 mM MDA in the absence (Fig. 3,
line EM) and in the presence of 50 Wg/ml K-crystallin
(Fig. 3, line EMC). During the incubation the en-
zyme lost 37% activity after 2 h and 57% after 6 h;
K-crystallin protected the enzyme, which lost only
11% of activity after 2 h and 30% after 6 h. K-Crys-
tallin did not a¡ect the activity of the unmodi¢ed
enzyme (Fig. 3, line EC). At the same concentration
K-crystallin provided total protection against enzyme
inactivation by glycation [20], whereas the protection
against MDA inactivation was only partial. The
chaperone activity of K-crystallin is not a¡ected by
MDA binding. Previous experiments showed that
K-crystallin can act as a chaperone under conditions
of oxidative stress [43]. Incubation of K-crystallin
with MDA concentrations between 1 mM and
100 mM did not impair the protective e¡ect against
thermal denaturation of LL-crystallin (B. Derham,
J.J. Harding, unpublished data). The partial protec-
tion of G6PD by K-crystallin against the inactivation
by MDA seems to be due to the high susceptibility of
the enzyme to MDA damage. Lower concentrations
of K-crystallin (10, 5 and 2 Wg/ml) were still protec-
tive under the conditions mentioned above, but less
so than 50 Wg/ml K-crystallin (E. Ganea, J.J. Har-
ding, unpublished data).
To check the speci¢city of the K-crystallin e¡ect,
Fig. 2. Inactivation of G6PD (0.5 U) incubated for 4 h with
various concentrations of MDA (0, 1, 2.5, 5 and 7.5 mM).
Fig. 3. G6PD activity after incubation in the absence (E) or
presence of 1 mM MDA (EM), in the presence of both 1 mM
MDA and 50 Wg/ml K-crystallin (EMC) and in the presence of
50 Wg/ml K-crystallin (EC).
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other proteins, namely BSA and lysozyme, at the
same concentration as K-crystallin, were incubated
with G6PD and MDA (Fig. 4). For this experiment,
the lowest protective concentration of K-crystallin
(2 Wg/ml) was used, and a shorter incubation time
(2 h), with the concentration of MDA increased to
5 mM. The activity of the enzyme incubated with
MDA decreased to 17% (Fig. 4, MDA), whereas in
the presence of 2 Wg/ml K-crystallin 31.2% activity
was still present after 2 h (Fig. 4, MDA+C). BSA
and lysozyme did not protect G6PD; the enzyme
incubated with MDA and BSA had 17% activity of
control (Fig. 4, MDA+BSA), and with MDA and
lysozyme 18.1% activity (Fig. 4, MDA+L), which
means zero and 1.1% protection, respectively. The
experiment clearly demonstrated the speci¢city of
the protective e¡ect of K-crystallin and also that a
smaller concentration of K-crystallin was still e¡ec-
tive.
The stoichiometry of the protective e¡ect of K-
crystallin against enzyme inactivation induced by gly-
cation [20] or by steroid binding [24] is consistent
with the proposed structural model by Carver et al.
[30], which suggests the protection of one molecule of
enzyme at each end of a cylindrical structure. The
present results show that one molecule of the enzyme
(G6PD) could be protected per aggregate of K-crys-
tallin if we take into account that the protection was
only partial (14.2%) during the incubation with 2 Wg/
ml K-crystallin. However, experiments performed on
glutathione reductase indicated that eight molecules
of enzyme could be protected by a single K-crystallin
aggregate [22]. The protection of G6PD by K-crystal-
lin against MDA inactivation is evident, but being
only partial, makes it di⁄cult to calculate the stoi-
chiometry. It appears that some protection of un-
folded protein is provided within the cavity of K-
crystallin, whereas more molecules can be bound to
the outside of K-crystallin aggregate. The actual
structure of the K-crystallin has not been determined
yet. As a consequence, the mechanism of the enzyme
protection against inactivation by MDA is di⁄cult to
establish. However, a cryo-electron microscopic
study indicates a cavity in the structure of K-crystal-
lin [31], and, recently, the X-ray structure of a sHSP
from M. jannaschii was determined and again
showed a cavity [32].
3.3. The e¡ect of K-crystallin on refolding G6PD after
MDA treatment
It is generally accepted that molecular chaperones
Fig. 5. G6PD inactivation by 1 mM MDA. After 6 h of incu-
bation, the unbound MDA was removed by dialysis against the
incubation bu¡er for 4 h, repeatedly changing the dialysis solu-
tion; the enzyme was further incubated in the absence
(E+MDA) or presence (E+MDA+C) of 50 Wg/ml K-crystallin.
Fig. 4. Incubation of G6PD for 2 h with 5 mM MDA in the
absence or in the presence of 2 Wg/ml of K-crystallin
(MDA+C), BSA (MDA+BSA) and lysozyme (MDA+L).
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interact with proteins and in£uence their correct
folding. HSP 90 can assist the refolding of citrate
synthase denatured by guanidinium chloride, without
ATP, in a molar ratio of one HSP 90 dimer binding
one or two molecules of non-native substrate protein
[44]. Recent results suggest that K-crystallin interacts
only with the partially unfolded proteins, and not
with native proteins. K-Lactalbumin forms a high
molecular weight complex with K-crystallin when
the former is in a disordered molten globule state
[45].
Our results concerning renaturation of MDA-dam-
aged G6PD by K-crystallin are illustrated in Fig. 5.
After 6 h of incubation with 1 mM MDA, the enzy-
mic activity has decreased to 58.8% of that at zero
time (Fig. 5). The e¡ect of 50 Wg/ml K-crystallin after
24 h of incubation with the dialysed sample was to
maintain this activity; the inactivation was 53% (line
E+MDA+C), whereas in the absence of K-crystallin
the inactivation went up to 77.2% (line E+MDA),
even though the unbound MDA has been removed.
The results demonstrate that although the enzyme is
not signi¢cantly renatured by K-crystallin, it is de¢-
nitely stabilised and protected from further denatu-
ration.
Raman et al. showed that K-crystallin prevented
aggregation of denatured-reduced lysozyme, but
had no e¡ect on the refolding of denatured-reduced
ribonuclease [46]. Recently it was shown that KB-
crystallin participated in the refolding of citrate syn-
thase [47], but the amount of reactivation was small
in the absence of ATP, and the reactivation was not
shown to be statistically signi¢cant. The di¡erence in
the ability of K-crystallin to prevent aggregation of
various enzymes, and the di¡erent stoichiometries of
protection discussed above, indicate that K-crystallin
can protect by more than one mechanism. Some pro-
teins may be protected in the cavity, others may be
protected on the surface of K-crystallin aggregates,
others could be protected dynamically, without form-
ing a stable complex.
3.4. Fluorescence spectra
Incubation of G6PD with MDA resulted in the
appearance of protein-bound £uorescence. Excitation
of the incubation mixture at various wavelengths
Fig. 7. Emission spectra (excitation 390 nm) of G6PD (0.184
mg/ml) incubated for 6 h with 5 mM MDA in the presence/ab-
sence of 50 Wg/ml K-crystallin. EM = G6PD+MDA;
EMC = G6PD+MDA+K-crystallin; CM =K-crystallin+MDA;
E = G6PD control; M = MDA.
Fig. 6. Emission spectra (excitation 335 nm, 350 nm, 370 nm
and 390 nm) of G6PD (0.184 mg/ml) incubated with 5 mM
MDA for 6 h. After incubation, unreacted MDA was removed
by intense dialysis against distilled water. Both native enzyme
and MDA incubated separately showed no signi¢cant £uores-
cence.
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yielded non-tryptophan £uorescence with emission
maxima at 460 nm (ex. 350, 370 and 390 nm) and
450 nm (ex. 335 nm) (Fig. 6). The native protein and
MDA, at the same concentrations as in the incuba-
tion mixture, were not £uorescent. The greatest in-
crease in the £uorescence was at the excitation wave-
length of 390 nm. A similar £uorescence spectrum,
390 nm ex./460 nm em. was previously demonstrated
for insoluble rat collagen incubated with MDA [48],
suggesting the presence of similar £uorophores in-
duced by MDA incubation with proteins. The 370/
440 nm £uorescence has been related to the Amadori
products of non-enzymic glycation and 335/385 nm
£uorescence related to pentosidine-like molecules
[48]. Schi¡ bases and Amadori compounds are ¢rst
produced by condensation of MDA with O-amino
groups of G6PD. The 350/460 nm £uorescence
(Fig. 6) indicates that other £uorophores are present,
besides the above-mentioned ones, after reaction of
G6PD with MDA. The various £uorescence spectra
suggest the presence of di¡erent MDA adducts to
protein, derived from rearrangement of the initial
adduct.
The emission £uorescence spectra (excitation 390
nm) for G6PD incubated with MDA in the presence
or absence of K-crystallin (see Section 2) show an
increase of the £uorescence intensity when K-crystal-
lin was also present (Fig. 7, line EMC). K-Crystallin
itself binds MDA, resulting in a £uorescent adduct.
MDA reacts with K-crystallin (at a higher MDA
concentration, 10 mM, and longer incubation time,
6 h) to generate a £uorescent compound associated
with protein polymerisation [13]. The emission spec-
trum of G6PD plus K-crystallin incubated with
MDA is approximately the sum of those of enzyme
and of K-crystallin alone (Fig. 7), indicating that K-
crystallin does not prevent chemical reactions of
G6PD and MDA that produce £uorophores. It
seems that protection by K-crystallin is not achieved
simply by it reacting with all available MDA. To
con¢rm this, bound MDA was measured by the
TBA method after incubation with enzyme alone,
K-crystallin alone, and enzyme plus K-crystallin,
under the same conditions as for £uorescence meas-
urements. 2.2, 1.2 and 3.3 WM MDA were bound to
protein in 1 ml reaction mixture, respectively. As the
results were additive, it is clear that K-crystallin is
not protecting the enzyme against the MDA reaction
itself. 67% of the MDA was bound by the enzyme
when K-crystallin was present.
Under these conditions with 5 mM MDA, there is
a great excess of MDA over the available reactive
Fig. 8. SDS-PAGE analysis of immunoprecipitates obtained with rabbit anti-G6PD and G6PD incubated without (lane 1) and with
2 Wg/ml K-crystallin (lane 2), 1 mM MDA (lane 3) and 2 Wg/ml K-crystallin+1 mM MDA (lane 4); lane 5 =K-crystallin, lane 6 =
G6PD, and lane 7 = molecular weight markers containing cytochrome c (12.3 kDa), myoglobin (17.2 kDa), carbonic anhydrase
(30 kDa), ovalbumin (42.7 kDa), albumin (66.25 kDa) and ovotransferrin (76^78 kDa).
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groups of K-crystallin, which would be the equivalent
of 0.0064 mM of arginine plus lysine. The K-crystal-
lin could not mop up all the MDA.
3.5. Complex formation as analysed by
immunoprecipitation
The mechanism of protection of enzymes by K-
crystallin against inactivation has not been estab-
lished. The nature of the interaction between enzyme
and K-crystallin could help our understanding of the
chaperone mechanism.
We have studied the interaction between G6PD
and K-crystallin by immuno-precipitation with anti-
G6PD (Fig. 8). K-Crystallin on SDS-PAGE migrates
as two bands of around 20 kDa (Fig. 8, lane 5),
representing KA- and KB-crystallins. Standard
G6PD migrates as a single band of 55 kDa as ex-
pected (Fig. 8, lane 6). In the immunoprecipitate of
G6PD incubated alone, or with MDA (Fig. 8, lanes 1
and 3, respectively) the band of G6PD is seen, but
there is no band in the position of K-crystallin. The
immunoprecipitate from the incubation of G6PD
with K-crystallin without MDA also shows no band
in the position of K-crystallin (Fig. 8, lane 2), where-
as after incubation of G6PD with both MDA and K-
crystallin (Fig. 8, lane 4) both G6PD and K-crystallin
were present in the immunoprecipitate. This indicates
that the G6PD damaged by MDA has formed a
complex with K-crystallin. This is the ¢rst demon-
stration of a protective complex between K-crystallin
and a chemically modi¢ed enzyme, by immunopreci-
pitation. The interaction between dithiothreitol-de-
natured K-lactalbumin and K-crystallin monitored
by 1H NMR suggested that the protein must be in
a disordered molten globule state for interaction to
occur [46]. The exact nature of the complex is not
clear, but as the structure of K-crystallin appears to
have a cavity, one might speculate that the damaged
G6PD was protected in the cavity. The stoichiometry
of protection supports this notion. The structure of
the sHSP from M. jannaschii not only has a cavity,
but it has pores that might provide access to the
cavity [32]. If K-crystallin, a similar sHSP, has a sim-
ilar structure, the pores might allow the access for a
target protein such as G6PD to be protected.
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